CD163 and neoplasm: In contrast, HRi-RBH tumors shared similarities with the mesenchymal subtype, demonstrating upregulation of immune evasion mechanisms, including anti-inflammatory pathways (e.g., IL-10, CD163) and EMT, suggesting these tumors rely on these mechanisms to promote tumor progression and evade immune detection.